Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Cash from Financing Activities: 2020-2024

Historic Cash from Financing Activities for Immuneering (IMRX) over the last 3 years, with Dec 2024 value amounting to -$40,988.

  • Immuneering's Cash from Financing Activities fell 623.14% to -$40,988 in Q4 2024 from the same period last year, while for Dec 2024 it was $5.3 million, marking a year-over-year decrease of 81.33%. This contributed to the annual value of $5.3 million for FY2024, which is 81.35% down from last year.
  • Latest data reveals that Immuneering reported Cash from Financing Activities of -$40,988 as of Q4 2024, which was down 100.94% from $4.4 million recorded in Q3 2024.
  • In the past 5 years, Immuneering's Cash from Financing Activities registered a high of $118.5 million during Q3 2021, and its lowest value of -$184,677 during Q4 2022.
  • Moreover, its 3-year median value for Cash from Financing Activities was $27,784 (2022), whereas its average is $3.1 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first tumbled by 2,556.14% in 2022, then surged by 101,297.86% in 2023.
  • Immuneering's Cash from Financing Activities (Quarterly) stood at $37.0 million in 2020, then plummeted by 99.98% to $7,519 in 2021, then plummeted by 2,556.14% to -$184,677 in 2022, then surged by 104.24% to $7,835 in 2023, then slumped by 623.14% to -$40,988 in 2024.
  • Its Cash from Financing Activities stands at -$40,988 for Q4 2024, versus $4.4 million for Q3 2024 and $979,923 for Q1 2024.